summit study tirzepatide Effects of on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the trial In pts wiht HFpEF and
Description
FDA-approved dual-mechanism oral medication
Payers are known to vary their level of control between different indications for the same drug and between different payer channels, and the GLP-1 market is no exception
Insurance approval for GLP-1 receptor agonists for weight loss typically requires BMI 30 kg/m OR BMI 27 kg/m with at least one weight-related comorbidity...
Gyms are embracing GLP-1s
Compounded tirzepatide offers an accessible alternative at lower cost when prescribed by a qualified healthcare provider
